Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences
January 08 2021 - 8:00AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing gene therapies to cure
blindness diseases and develop a vaccine to fight COVID-19, today
announced that it will present at the 2021 CTIC 5th Healthcare
Investment Summit being held on January 9-10, the H.C. Wainwright
BioConnect Conference being held on January 11-14, and the Noble
Capital Markets 17th Annual Small and Microcap Investor Conference
being held on January 19-21.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present
virtually at all three conferences to provide an update on the
development of Ocugen’s breakthrough modifier gene therapy, its
novel biologic product candidate, and COVID-19 vaccine candidate,
COVAXIN™ for the US market. Dr. Musunuri will share Ocugen’s recent
accomplishments and its plans to initiate four Phase 1/2 clinical
trials within 1-2 years.
Presentation Details:
Conference: CTIC 5th
Healthcare Investment
SummitFormat: Company
PresentationDate: Saturday, January 9 – Wednesday,
January 13, 2021Time: On
demandRegistration Link:
https://www.eventbrite.com/e/ctic-5th-pre-jpm-healthcare-investment-summit-tickets-128559391601
Conference: H.C. Wainwright BioConnect 2021
ConferenceFormat: Company
PresentationDate: Monday, January 11 – Thursday,
January 14, 2021Time: On demand during conference
beginning at 6 am EST on January 11Webcast Link:
https://journey.ct.events/view/e6cc3d68-15d4-435c-85b2-82deba0a807e
Conference: Noble Capital Markets
17th Annual Small and Microcap
Investor ConferenceFormat: Company
PresentationDate: Wednesday, January 20, 2021;
Recording available on January 21Time:
10:30 am EST – Track 1Webcast Link:
https://noble.mediasite.com/Mediasite/Play/0c739853fbf144548d1287c95d16da3d1d
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
develop a vaccine to fight COVID-19. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with one drug – “one to many” and our novel biologic
product candidate aims to offer better therapy to patients with
underserved diseases such as wet age-related macular degeneration,
diabetic macular edema, and diabetic retinopathy. For more
information, please visit www.ocugen.com.
About COVAXIN™COVAXIN™, India's COVID-19
vaccine candidate by Bharat Biotech is developed in collaboration
with the Indian Council of Medical Research (ICMR) - National
Institute of Virology (NIV). This inactivated vaccine is developed
and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio
containment facility. COVAXIN™ is a highly purified and inactivated
vaccine, manufactured in a vero cell manufacturing platform with an
excellent safety track record of more than 300 million doses
supplied. COVAXIN™ recently received Emergency Use Authorization
(EUA) from the Indian government. Ocugen and Bharat Biotech
recently entered into a binding letter of intent to co-develop
COVAXIN™ for the US Market.
Cautionary Note on Forward-Looking
StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and
Exchange Commission (the “SEC”), including the risk factors
described in the section entitled “Risk Factors” in the quarterly
and annual reports that we file with the SEC. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact: LaVoieHealthScience Emmie
Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024